Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: Tolerance, cross-tolerance, and blockade by naloxone

Psychopharmacology

Volumn 198, Issue 2, 2008, Pages 167-180

  Glover, Ebony M ^a,b   Davis, Michael ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Fear conditioning; Opioid; Startle; Tolerance; Withdrawal

Indexed keywords

BUPRENORPHINE; MORPHINE; NALOXONE; SODIUM CHLORIDE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEAR; INJECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STARTLE REFLEX; TAIL FLICK TEST; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BUPRENORPHINE; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEAR; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 43149091199     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1112-0     Document Type: Article

References (65)

1. Anseloni VC, Coimbra NC, Morato S, Brandao ML (1999) A comparative study of the effects of morphine in the dorsal periaqueductal gray and nucleus accumbens of rats submitted to the elevated plus-maze test. Exp Brain Res 129:260-268
2. Asakawa A, Inui A, Momose K, Ueno N, Fujino MA, Kasuga M (1998) Endomorphins have orexigenic and anxiolytic activities in mice. Neuroreport 9:2265-2267
3. Bailey KP (2004) Pharmacological treatments for substance use disorders. J Psychosoc Nurs Ment Health Serv 42:14-20
4. Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ (2001) Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl) 158:154-164
5. Bartoletti M, Gaiardi M, Gubellini C, Bacchi A, Babbini M (1990) Morphine attenuation of a conditioned emotional response in post-dependent rats. Eur J Pharmacol 185:163-167
6. Behbehani MM (1995) Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46:575-605
7. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141-1146
8. Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:49-57
9. Cassella JV, Davis M (1986) The design and calibration of a startle measurement system. Physiol Behav 36:377-383
10. Cowan A (2003) Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 3-8:23-24 discussion
11. Cowan A, Lewis JW, Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545
12. Craft RM, Dykstra LA (1990) Differential cross-tolerance to opioids in squirrel monkeys responding under a shock titration schedule. J Pharmacol Exp Ther 252:945-952
13. Davis M (1979a) Morphine and naloxone: effects on conditioned fear as measured with the potentiated startle paradigm. Eur J Pharmacol 54:341-347
14. Davis M (1979b) Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1-7
15. Davis M, Whalen PJ (2001) The amygdala: vigilance and emotion. Mol Psychiatry 6:13-34
16. Davis M, Redmond DE, Baraban JM (1979) Noradrenergic agonists and antagonists: effects o conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology 65:111-118
17. Davis M, Falls WA, Campeau S, Kim M (1993) Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58:175-198
18. Fendt M, Mucha RF (2001) Anxiogenic-like effects of opiate withdrawal seen in the fear-potentiated startle test, an interdisciplinary probe for drug-related motivational states. Psychopharmacology (Berl) 155:242-250
19. Fernandez F, Misilmeri MA, Felger JC, Devine DP (2004) Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29:59-71
20. File SE, Rodgers RJ (1979) Partial anxiolytic action of morphine sulphate following microinjection into the central nucleus of the amygdala in rats. Pharmacol Biochem Behav 11:313-318
21. Fox RJ, Sorenson CA (1994) Bilateral lesions of the amygdala attenuate analgesia induced by diverse environmental challenges. Brain Res 648:215-221
22. Fudala PJ, Johnson RE, Jaffe JH (1990) Outpatient comparison of buprenorphine and methadone maintenance. II. Effects on cocaine usage, retention time in study and missed clinic visits. NIDA Res Monogr 105:587-588
23. Gellert VF, Holtzman SG (1978) Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205:536-546
24. Good AJ, Westbrook RF (1995) Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Behav Neurosci 109:631-641
25. Gowing L, Ali R, White J (2002) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev CD002025
26. Gringauz M, Rabinowitz R, Stav A, Korczyn AD (2001) Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth 15:204-209
27. Hall SM (1984) The abstinence phobias: links between substance abuse and anxiety. Int J Addict 19:613-631
28. Harris AC, Gewirtz JC (2004) Elevated startle during withdrawal from acute morphine: a model of opiate withdrawal and anxiety. Psychopharmacology (Berl) 171:140-147
29. Hawkinson JE, Acosta-Burruel M, Espitia SA (2000) Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 389:107-114
30. Helmstetter FJ, Bellgowan PS (1993) Lesions of the amygdala block conditional hypoalgesia on the tail flick test. Brain Res 612:253-257
31. Helmstetter FJ, Bellgowan PS, Tershner SA (1993) Inhibition of the tail flick reflex following microinjection of morphine into the amygdala. Neuroreport 4:471-474
32. Hitchcock J, Davis M (1986) Lesions of the amygdala, but not of the cerebellum or red nucleus, block conditioned fear as measured with the potentiated startle paradigm. Behav Neurosci 100:11-22
33. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695
34. Huyser BA, Parker JC (1999) Negative affect and pain in arthritis. Rheum Dis Clin North Am 25:105-121 vi
35. Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 29:1656-1663
36. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501-516
37. Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ Jr., Nothacker HP, Civelli O (1997) Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci USA 94:14854-14858
38. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Kolczewski S, Adam G, Kilpatrick G (2000) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci USA 97:4938-4943
39. Kameyama T, Nagasaka M (1982) The effects of analgesics on quickly-learned conditioned suppression in mice. Neuropharmacology 21:1283-1289
40. Kehne JH, Cassella JV, Davis M (1988) Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 94:8-13
41. Koks S, Soosaar A, Voikar V, Bourin M, Vasar E (1999) BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33:63-69
42. Le Guen S, Gestreau C, Besson JM (2001) Sensitivity to naloxone of the behavioral signs of morphine withdrawal and c-Fos expression in the rat CNS: a quantitative dose-response analysis. J Comp Neurol 433:272-296
43. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363-372
44. Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharm 2:395-402
45. Manning BH, Mayer DJ (1995) The central nucleus of the amygdala contributes to the production of morphine antinociception in the formalin test. Pain 63:141-152
46. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823
47. McWilliams LA, Cox BJ, Enns MW (2003) Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 106:127-133
48. Meis S, Pape HC (1998) Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J Neurosci 18:8133-8144
49. Motta V, Brandao ML (1993) Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol Biochem Behav 44:119-125
50. Moulin DE, Ling GS, Pasternak GW (1988) Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 33:233-239
51. Privette TH, Terrian DM (1995) Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology (Berl) 118:444-450
52. Rodgers RJ (1978) Influence of intra-amygdaloid opiate injections on shock thresholds, tail-flick latencies and open field behaviour in rats. Brain Res 153:211-216
53. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374-380
54. Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK (2002) The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res Bull 57:689-694
55. Schulteis G, Yackey M, Risbrough V, Koob GF (1998) Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze. Pharmacol Biochem Behav 60:727-731
56. Shin IC, Kim HC, Swanson J, Hong JT, Oh KW (2003) Anxiolytic effects of acute morphine can be modulated by nitric oxide systems. Pharmacology 68:183-189
57. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549
58. Stinus L, Cador M, Zorrilla EP, Koob GF (2005) Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30:90-98
59. Tzschentke TM (2002) Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 161:1-16
60. Uriguen L, Fernandez B, Romero EM, De Pedro N, Delgado MJ, Guaza C, Schmidhammer H, Viveros MP (2002) Effects of 14-methoxymetopon, a potent opioid agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Res Bull 57:661-666
61. Walker EA, Young AM (2001) Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl) 154:131-142
62. Wall PM, Messier C (2000) U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice. Brain Res 856:259-280
63. Wichmann J, Adam G, Rover S, Hennig M, Scalone M, Cesura AM, Dautzenberg FM, Jenck F (2000) Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen- 1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 35:839-851
64. Wnendt S, Kruger T, Janocha E, Hildebrandt D, Englberger W (1999) Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 56:334-338
65. Wright RC, Ingenito AJ (2001) Prevention of isolation-induced hypertension by intrahippocampal administration of a nonpeptide kappa-opioid receptor agonist. Hippocampus 11:445-451